Cytokinetics (CYTK) announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium on Friday, May 30th, 2025. The event will be held at the Mission Bay Conference Center in San Francisco, CA. “CLIMB was born out of our vision to bring together key contributors in muscle biology across academia and industry to foster meaningful scientific exchange and showcase novel research,” said Fady Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As pioneers and leaders in muscle biology, we remain committed to advancing the field by deepening collective understandings underlying muscle-related diseases and disorders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
- Promising Phase 3 Results for Aficamten Boost Cytokinetics’ Market Position in Hypertrophic Cardiomyopathy Treatment
- Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption
- Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
- Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue